### HUMAN CANCER BIOLOGY

**3401** Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions  
Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

**3411** MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array  
Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahara Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier  
*See related article, p. 3361*

**3422** Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer  
Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Offringa, Jens Werner, and Eduard Ryschich

**3434** Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer  
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

### CANCER THERAPY: PRECLINICAL

**3446** Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma  
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglio, Bjoern Titz, Thilie Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
Table of Contents

3458 Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

3472 Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang

3485 Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser

3496 Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
Giannaria Liccardi, John A. Hartley, and Daniel Hochhauser

3507 Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

3521 Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandra T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong

IMAGING, DIAGNOSIS, PROGNOSIS

3531 In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
Yasaman Ardestirpour, Victor Chernomordik, Moinuddin Hassan, Rafal Zielinski, Jacek Capala, and Amir Gandelakhche

3540 Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
Katja Pinker, Wolfgang Bogner, Pascal Balzer, Georgios Karanikas, Heinrich Magometschnigg, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dubsky, Zsuzsanna Bago-Horvath, Rupert Bartsch, Michael Weber, Siegfried Trattnick, and Thomas H. Helbich

3550 Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Gliona on Bevacizumab Therapy
Johannes Schwarzenberg, Johannes Czernin, Timothy F. Cloughesy, Benjamin M. Ellingson, Whitney B. Pope, Tristan Grogon, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen

3560 Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm
Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yongqiang Tan, Jing Qi, Thorsten Persienghl, David P. Mozley, and Lawrence H. Schwartz

3569 TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Berresne-Dale, Carlos Caldas, and Anita Langerod

CANCER THERAPY: CLINICAL

3581 A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

3589 Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herndlhofe, Berthold Streubel, Werner Rabitsch, Wolfgang R. Speer, Matthias Mayerhofer, Thomas Kulicke, and Peter Valen
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiro Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

LETTERS TO THE EDITOR

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihuaxia Xiong, and Xianglin Yuan

ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.